Table A2.
Pooled risk ratios in the main and sensitivity analyses.
| Stratification | Approaches | CNS Effect | Sleep Related Effect |
|---|---|---|---|
| All included studies | Inverse variance with 0.5 continuity correction (main analysis) | 1.16 (0.64–2.12) | 1.67 (0.91–3.07) |
| Inverse variance with “treatment-arm” continuity correction | 1.14 (0.61–2.11) | 1.35 (0.84–2.17) | |
| Mantel-Haenszel | 1.15 (0.62–2.15) | 1.35 (0.84–2.17) | |
| Beta-binomial with correlated responses | 0.45 (0.14–1.53) | 1.96 (0.46–8.43) | |
| Studies with comparison group of corticosteroids | Inverse variance with 0.5 continuity correction | 0.27 (0.02–3.00) | |
| Inverse variance with “treatment-arm” continuity correction | 0.27 (0.03–2.81) | ||
| Mantel-Haenszel | 0.27 (0.02–4.49) | ||
| Beta-binomial with correlated responses | 0.05 (0.003–1.10) | ||
| Studies with comparison group of placebo | Inverse variance with 0.5 continuity correction | 1.35 (0.83–2.11) | 1.55 (0.82–2.92) |
| Inverse variance with “treatment-arm” continuity correction | 1.35 (0.83–2.11) | 1.55 (0.82–2.92) | |
| Mantel-Haenszel | 1.35 (0.83–2.11) | 1.55 (0.82–2.92) | |
| Beta-binomial with correlated responses | 1.40 (0.6–3.30) | 1.44 (0.43–4.84) | |
| Studies with comparison group of non-corticosteroids | Inverse variance with 0.5 continuity correction | 1.40 (0.86–2.27) | 1.63 (0.88–3.03) |
| Inverse variance with “treatment-arm” continuity correction | 1.40 (0.86–2.27) | 1.63 (0.88–3.03) | |
| Mantel-Haenszel | 1.40 (0.86–2.27) | 1.63 (0.88–3.03) | |
| Beta-binomial with correlated responses | 1.70 (0.60–5.16) | 1.77 (0.56–5.55) |